# US 2005/0238706 A1 · Pharmaceutically active lipid based formulation of SN-38

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0238706 A1
- Document ID: US20050238706A1
- Status: Published application
- Kind: A1
- Application number: 11/061,044
- Filed: 2005-02-18
- Published: 2005-10-27
- Earliest claimed: 2002-08-20
- Assignees: NeoPharm, Inc.
- Inventors: Imran Ahmad; Jia-Ai Zhang
- Web page: https://patentgrep.com/patent/US20050238706A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes. The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN38 into complexes and are capable of solubilizing relatively high concentrations of SN38.

## Claims

### Claim 1

A method of treating viral infections comprising administering to a patient having a viral infection a composition comprising a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the viral infection within the patient.

### Claim 2

A method of treating pancreatic cancer in a patient comprising administering to a patient having pancreatic cancer a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the cancer within the patient.

### Claim 3

A method of treating a disease caused by proliferating eukaryotic cells in a patient homozygous for the wild-type UGTA1 allele or having at least one copy of the UGTA1*28 allele comprising administering to a patient having a disease caused by proliferating eukaryotic cells a complex comprising SN38 or a chemical in equilibrium with SN38 and a lipid to the patient in an amount sufficient to treat the disease caused by proliferating eukaryotic cells within the patient, wherein the patient has at least one copy of the UGTA1 allele.

### Claim 4

A method of administering a composition comprising a composition selected from SN38 or a chemical in equilibrium with SN38 and a lipid to a human patient, wherein the composition is administered over a period of from about 30 to about 180 minutes.

### Claim 5

A method of forming a lipid composition comprising an agent selected from SN38 or a chemical in equilibrium with SN38, involving forming a lipid phase and thereafter hydrating the lipid phase with a first aqueous solution including the compound so as to form lipid composition including the compound, and thereafter reducing the pH of the lipid composition, wherein the pH is reduced to less than 3.5.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pH is between about 1.5 and about 3.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pH is about 2.0.

### Claim 8 (depends on 5)

The method of claim 5, wherein the lipid phase comprises cardiolipin.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cardiolipin is selected from a group consisting of natural cardiolipin, synthetic cardiolipin, and chemically modified cardiolipin.

### Claim 10 (depends on 8)

The method of claim 8, wherein the lipid phase further comprises one or more lipids selected from a group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, phosphatidylinositol, sphingomyelin, sterol, tocopherol, fatty acid, ganglioside GM1 and polymer modified lipids, such as PEG modified lipids, and mixtures thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the phosphatidylglycerol is selected from a group consisting of dimyristoylphosphatidylglycerol, dioleoylphosphatidylglycerol, distearoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, or mixtures thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the phosphatidylcholine is selected from a group consisting of dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoyl phosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.

### Claim 13 (depends on 10)

The method of claim 10, wherein the sterol is selected from a group consisting of cholesterol, polyethylene glycol derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.

### Claim 14 (depends on 10)

The method of claim 10, wherein the lipid phase consists of a phosphatidylcholine, a sterol, and a tocopherol.

### Claim 15 (depends on 5)

The method of claim 5, wherein the lipid phase is formed in an organic solvent.

### Claim 16 (depends on 15)

The method of claim 15, further involving evaporating the solvent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the evaporation occurs prior to reducing the pH of the composition.

### Claim 18 (depends on 5)

The method of claim 5, wherein the first aqueous solution is a solubilizing agent that is employed to increase the solubility of SN38.

### Claim 19 (depends on 18)

The method of claim 18, wherein the solubilizing agent has an alkaline pH.

### Claim 20 (depends on 19)

The method of claim 19, wherein the solubilizing agent is selected from a group consisting of sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium phosphate, ammonium acetate, sodium citrate, sodium hydroxide, calcium hydroxide, sodium biphosphate, sodium phosphate, Tris (hydroxy-methyl) aminomethane and sodium benzoate.

### Claim 21 (depends on 19)

The method of claim 19, wherein the pH of the first aqueous solution is between about 7 and about 11.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pH of the first aqueous solution is between about 8 and about 10.

### Claim 23 (depends on 5)

The method of claim 5, wherein the hydration step is performed with vigorous mixing.

### Claim 24 (depends on 5)

The method of claim 5, further involving the addition of one or more agents to enhance the shelf-life of the SN38 composition.

### Claim 25 (depends on 24)

The method of claim 24, wherein the agent comprises one or more sugars.

### Claim 26 (depends on 5)

The method of claim 5, further involving filtering the lipid composition.

### Claim 27 (depends on 26)

The method of claim 26, wherein the filtration occurs prior to reducing the pH of the composition.

### Claim 28 (depends on 26)

The method of claim 26, wherein the filtration is through a filter of about 5 microns or less.

### Claim 29 (depends on 28)

The method of claim 28, wherein the filtration is through a filter of about 1 micron or less.

### Claim 30 (depends on 29)

The method of claim 29, wherein the filtration is through a filter of about 500 nm or less.

### Claim 31 (depends on 30)

The method of claim 30, wherein the filtration is through a filter of about 200 nm or less.

### Claim 32 (depends on 31)

The method of claim 31, wherein the filtration is through a filter of about 100 nm or less.

### Claim 33 (depends on 5)

The method of claim 5, further involving dehydrating the lipid composition to form a dried lipid composition.

### Claim 34 (depends on 33)

The method of claim 33, wherein the dehydrating occurs prior to reducing the pH of the composition.

### Claim 35 (depends on 33)

The method of claim 33, wherein the dehydrating occurs after reducing the pH of the composition.

### Claim 36 (depends on 5)

A liposomal composition comprising a compound selected from SN38 or a chemical in equilibrium with SN38 and one or more lipids, wherein said composition is produced in accordance with the method of claim 5.

### Claim 37 (depends on 36)

The liposomal composition of claim 36, wherein 95 wt. % or more of the compound is in a complex with a portion of the lipid.

### Claim 38 (depends on 36)

The composition of claim 36, wherein the compound is SN38.

### Claim 39 (depends on 36)

The composition of claim 36, wherein the concentration of the compound in the composition is about 0.1 or more to about 20 mg/ml.

### Claim 40 (depends on 36)

The composition of claim 36, wherein the concentration of the compound is about 0.01 or more to about 5 mg/ml.

### Claim 41 (depends on 36)

The composition of claim 36, wherein the concentration of the compound is about 0.1 or more to about 4 mg/ml.

### Claim 42 (depends on 36)

The composition of claim 36, wherein the concentration of the compound is about 0.5 or more to about 3 mg/ml.

### Claim 43 (depends on 36)

The composition of claim 36, wherein the concentration of the compound is about 0.8 or more to about 2 mg/ml.

### Claim 44 (depends on 36)

The composition of claim 36, wherein the concentration of the compound is about 1 or more to about 1.5 mg/ml.

### Claim 45 (depends on 36)

The composition of claim 36, wherein the lipid comprises cardiolipin.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the cardiolipin is selected from a group consisting of natural cardiolipin, synthetic cardiolipin, and chemically modified cardiolipin.

### Claim 47 (depends on 45)

The composition of claim 45, wherein the lipid further comprises one or more lipids selected from a group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, phosphatidylinositol, sphingomyelin, sterol, tocopherol, fatty acid, ganglioside GM1 and polymer modified lipids, such as PEG modified lipids, and mixtures thereof.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the phosphatidylglycerol is selected from a group consisting of dimyristoylphosphatidylglycerol, dioleoylphosphatidylglycerol, distearoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, or mixtures thereof.

### Claim 49 (depends on 47)

The composition of claim 47, wherein the phosphatidylcholine is selected from a group consisting of dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoyl phosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.

### Claim 50 (depends on 47)

The composition of claim 47, wherein the sterol is selected from a group consisting of cholesterol, polyethylene glycol derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.

### Claim 51 (depends on 47)

The composition of claim 47, wherein the lipid consists of a phosphatidylcholine, a sterol, and a tocopherol.

### Claim 52 (depends on 36)

The composition of claim 36, wherein the liposomes have a diameter of about 1 micron or less.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the liposomes have a diameter of about 200 nm or less.

### Claim 54 (depends on 53)

The composition of claim 53, wherein the liposomes have a diameter of about 100 nm or less.

### Claim 55 (depends on 36)

The composition of claim 36, further including a pharmaceutically acceptably excipient.

### Claim 56 (depends on 36)

The composition of claim 36, further including a targeting agent.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the targeting agent is a protein.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the protein is selected from a group consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands, and mixtures thereof.

### Claim 59 (depends on 56)

The composition of claim 56, wherein the targeting agent is a carbohydrate.
